

OL GAV

Please type a plus sign (+) inside this box +

Attorney Docket P1872R1

PATENT

EV 016026425 US: Express Mail Number

February 15 2002 Date of Deposit



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION Assistant Commissioner of Patents Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Venita I. DeAlmeida, San Mateo, California Timothy A. Stewart, San Francisco, California

Title:	TREATMENT INVOLVING DKK-1 OR ANTAGONISTS THER	EOF
--------	---	-----

- 1. Type of Application
- [] This application is for an original, non-provisional application.
- [X] This is a non-provisional application claiming priority to provisional application no. 60/269,435 , filed ___February 16, 2001 , the entire disclosure of which is hereby incorporated by reference.
- [] This is a [] continuation-in-part [] continuation [] divisional application claiming priority to application Serial Number__, filed ___, the entire disclosure of which is hereby incorporated by reference.
- 2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Non-provisional)
 - 55 pages of specification
 - _3_ pages of claims
 - __1__ page(s) of abstract
- 3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

til selt ner i

100

4.

5.

<u>X</u>	An executed declaration of the inventor(s) [] is enclosed [X] will follow.
	(for Cont./Div. where inventorship is the same or inventor(s) being deleted) A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).
	(for Cont./Div. where inventor(s) being deleted) A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).
Assi	gnment
X	(for new and CIP applications) An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [X] will follow.
	(for cont./div.) The prior application is assigned of record to Genentech, Inc.
Ame	ndments (for continuation and divisional applications)
	Cancel in this application original claims of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
	A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

		saloulated do 10			202
Marian Marian		CLAIM	S FOR FEE CA	LCULATION	Management of the Control of the Con
Number	Eled	5,050, c	FEXITA	Rate	Ab., 49444 . 19444 . 19477 19464
Total Claims	52	- 20 =	32	X \$18.00	\$576.00
Independent Claims	14	- 3=	11	X \$84.00	\$858.00
	\$0.00				
	\$2,174.00				

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$2,174.00. A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

9. Additiona	l Papers l	Enclosed
--------------	------------	----------

- [] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- [X] Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- [] A new Power of Attorney or authorization of agent.
- [] Other:

10.	Maintenance	of	Copendency	of	Prior	Application	(for	continuation	and	divisional
applica	ations)									

[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

A petition, fee and/or response has been filed to extend the term in
the pending prior application until
 A copy of the petition for extension of time in the <i>prior</i> application
is attached.

11. Correspondence Address:

X Address all future communications to:

Attn: Janet E. Hasak

Respectfully submitted, GENENTECH, INC.

Date: February 32, 2002

Janet E. Hasak

Reg. No. 28,616 Telephone No. (650) 225-1896

09157

PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Venita I. DeAlmeida et al.

Serial No.: Unassigned

Filed:

15 February 2002

(Filed herewith)

For: TREATMENT INVOLVING DKK-1 OR

ANTAGONISTS THEREOF

Group Art Unit: Unassigned

Examiner: Unassigned

CERTIFICATION UNDER 37 CFR 1.10

EV 016026425 US: Express Mail Number February 15, 2002: Date of Deposit

I hereby certify that this correspondence, consisting of Non-Provisional Application Transmittal, specification, Certificate Re: Sequence Listing Response Under 37 CFR §1.821(f), Sequence Listing, Diskette, postcard, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Pamela Gavette

CERTIFICATE RE: SEQUENCE LISTING RESPONSE UNDER 37 CFR § 1.821(f)

BOX PATENT APPLICATION Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the information recorded in computer readable form is identical to the written sequence listing.

Respectfully submitted,

GENENTECH, INC.

Date: February 13, 2002

Reg. No. 28,616

Telephone No. (650) 225-1896

PATENT TRADEMARK OFFICE